Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smith & Nephew rewarded for swift action in knee recall

This article was originally published in Clinica

Executive Summary

Smith & Nephew is keen to minimise the significance of its US Oxinium knee implant recall, and by the look of its share price, investors at least are inclined to give it the benefit of the doubt. Its stock price slipped by less than 2% after it announced the voluntary recall of a limited number of cement-free knee replacements on September 17, and the following day the shares regained most of the lost ground.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel